Skip to main content
NCBI home page
International Journal of Experimental Pathology logoLink to International Journal of Experimental Pathology
. 1994 Aug;75(4):257–263.

Evaluating the response to antioestrogen toremifene treatment in DMBA induced rat mammary carcinoma.

R Huovinen 1, P L Kellokumpu-Lehtinen 1, Y Collan 1
PMCID: PMC2002236  PMID: 7947228

Abstract

Evaluation of the treatment response to hormonal therapy in experimental mammary carcinoma models usually consists of recording the changes in tumour volume or in number of tumours. We performed quantitative histology on dimethylbenz[a]anthracene(DMBA) induced rat mammary carcinoma treated with the antioestrogen toremifene. The inhibition of growth of the treated regressing tumours was not only associated with inhibition of mitosis and reduction of the neoplastic epithelium, but toremifene seemed to reduce all main tissue components. The percentual area fractions of epithelium and stroma were equal in the untreated and the treated tumours. The estimated absolute volumes of epithelium, stroma and glandular luminae as well as the mitotic index were significantly reduced during toremifene treatment in those tumours which were responding by regression to the treatment. The findings indicate growth inhibiting effect on both epithelium and stroma or on interactions between epithelium and stroma. Adding quantitative histology to the gross response analysis in experimental animal models is feasible and may elucidate the mechanisms of action of a novel hormonal treatment.

Full text

PDF
257

Images in this article

260Figure 2
on p.260

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer F. L., Orlando R. A. Morphology, natural history, and enzyme patterns in mammary tumors of the rat induced by 7,12-dimethylbenz(a)anthracene. Cancer Res. 1968 Feb;28(2):217–224. [PubMed] [Google Scholar]
  2. Bakker G. H., Setyono-Han B., Henkelman M. S., de Jong F. H., Lamberts S. W., van der Schoot P., Klijn J. G. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treat Rep. 1987 Nov;71(11):1021–1027. [PubMed] [Google Scholar]
  3. Bardon S., Vignon F., Montcourrier P., Rochefort H. Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res. 1987 Mar 1;47(5):1441–1448. [PubMed] [Google Scholar]
  4. Brooks M. D., Ebbs S. R., Colletta A. A., Baum M. Desmoid tumours treated with triphenylethylenes. Eur J Cancer. 1992;28A(6-7):1014–1018. doi: 10.1016/0959-8049(92)90445-8. [DOI] [PubMed] [Google Scholar]
  5. Brünner N., Bronzert D., Vindeløv L. L., Rygaard K., Spang-Thomsen M., Lippman M. E. Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res. 1989 Mar 15;49(6):1515–1520. [PubMed] [Google Scholar]
  6. Butta A., MacLennan K., Flanders K. C., Sacks N. P., Smith I., McKinna A., Dowsett M., Wakefield L. M., Sporn M. B., Baum M. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 1992 Aug 1;52(15):4261–4264. [PubMed] [Google Scholar]
  7. Colletta A. A., Wakefield L. M., Howell F. V., van Roozendaal K. E., Danielpour D., Ebbs S. R., Sporn M. B., Baum M. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer. 1990 Sep;62(3):405–409. doi: 10.1038/bjc.1990.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Escrich E. Validity of the DMBA-induced mammary cancer model for the study of human breast cancer. Int J Biol Markers. 1987 Sep-Dec;2(3):197–206. doi: 10.1177/172460088700200312. [DOI] [PubMed] [Google Scholar]
  9. HUGGINS C., YANG N. C. Induction and extinction of mammary cancer. A striking effect of hydrocarbons permits analysis of mechanisms of causes and cure of breast cancer. Science. 1962 Jul 27;137(3526):257–262. doi: 10.1126/science.137.3526.257. [DOI] [PubMed] [Google Scholar]
  10. Haapasalo H., Pesonen E., Collan Y. Volume corrected mitotic index (M/V-INDEX). The standard of mitotic activity in neoplasms. Pathol Res Pract. 1989 Nov;185(5):551–554. doi: 10.1016/S0344-0338(89)80191-8. [DOI] [PubMed] [Google Scholar]
  11. Huovinen R., Wärri A., Collan Y. Mitotic activity, apoptosis and TRPM-2 mRNA expression in DMBA-induced rat mammary carcinoma treated with anti-estrogen toremifene. Int J Cancer. 1993 Oct 21;55(4):685–691. doi: 10.1002/ijc.2910550429. [DOI] [PubMed] [Google Scholar]
  12. Jordan V. C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer. 1976 Jun;12(6):419–424. doi: 10.1016/0014-2964(76)90030-x. [DOI] [PubMed] [Google Scholar]
  13. Jordan V. C. Estrogen receptor-mediated direct and indirect antitumor effects of tamoxifen. J Natl Cancer Inst. 1990 Nov 7;82(21):1662–1663. doi: 10.1093/jnci/82.21.1662. [DOI] [PubMed] [Google Scholar]
  14. Jordan V. C. Laboratory models of breast cancer to aid the elucidation of antiestrogen action. J Lab Clin Med. 1987 Mar;109(3):267–277. [PubMed] [Google Scholar]
  15. Kallio S., Kangas L., Blanco G., Johansson R., Karjalainen A., Perilä M., Pippo I., Sundquist H., Södervall M., Toivola R. A new triphenylethylene compound, Fc-1157a. I. Hormonal effects. Cancer Chemother Pharmacol. 1986;17(2):103–108. doi: 10.1007/BF00306736. [DOI] [PubMed] [Google Scholar]
  16. Kangas L., Nieminen A. L., Blanco G., Grönroos M., Kallio S., Karjalainen A., Perilä M., Södervall M., Toivola R. A new triphenylethylene compound, Fc-1157a. II. Antitumor effects. Cancer Chemother Pharmacol. 1986;17(2):109–113. doi: 10.1007/BF00306737. [DOI] [PubMed] [Google Scholar]
  17. Knabbe C., Lippman M. E., Wakefield L. M., Flanders K. C., Kasid A., Derynck R., Dickson R. B. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell. 1987 Feb 13;48(3):417–428. doi: 10.1016/0092-8674(87)90193-0. [DOI] [PubMed] [Google Scholar]
  18. Lerner L. J., Jordan V. C. Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res. 1990 Jul 15;50(14):4177–4189. [PubMed] [Google Scholar]
  19. Manni A., Trujillo J. E., Pearson O. H. Predominant role of prolactin in stimulating the growth of 7, 12-dimethylbenz(a)anthracene-induced rat mammary tumor. Cancer Res. 1977 Apr;37(4):1216–1219. [PubMed] [Google Scholar]
  20. Michna H., Gehring S., Kühnel W., Nishino Y., Schneider M. R. The antitumor potency of progesterone antagonists is due to their differentiation potential. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):203–210. doi: 10.1016/0960-0760(92)90209-2. [DOI] [PubMed] [Google Scholar]
  21. Nicholson R. I., Kéri G. Antitumour activity of folligen, a novel gonadotropin-releasing hormone analogue against DMBA-induced tumours in the rat. Tumour Biol. 1992;13(1-2):44–50. doi: 10.1159/000217751. [DOI] [PubMed] [Google Scholar]
  22. Osborne C. K., Boldt D. H., Estrada P. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res. 1984 Apr;44(4):1433–1439. [PubMed] [Google Scholar]
  23. Osborne C. K., Hobbs K., Clark G. M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985 Feb;45(2):584–590. [PubMed] [Google Scholar]
  24. Reissmann T., Hilgard P., Harleman J. H., Engel J., Comaru-Schally A. M., Schally A. V. Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone. J Cancer Res Clin Oncol. 1992;118(1):44–49. doi: 10.1007/BF01192310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Robinson S. P., Mauel D. A., Jordan V. C. Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. Eur J Cancer Clin Oncol. 1988 Dec;24(12):1817–1821. doi: 10.1016/0277-5379(88)90091-0. [DOI] [PubMed] [Google Scholar]
  26. Sawhney N., Garrahan N., Douglas-Jones A. G., Williams E. D. Epithelial--stromal interactions in tumors. A morphologic study of fibroepithelial tumors of the breast. Cancer. 1992 Oct 15;70(8):2115–2120. doi: 10.1002/1097-0142(19921015)70:8<2115::aid-cncr2820700818>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  27. Valavaara R., Pyrhönen S., Heikkinen M., Rissanen P., Blanco G., Thölix E., Nordman E., Taskinen P., Holsti L., Hajba A. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol. 1988 Apr;24(4):785–790. doi: 10.1016/0277-5379(88)90316-1. [DOI] [PubMed] [Google Scholar]
  28. Weibel E. R., Kistler G. S., Scherle W. F. Practical stereological methods for morphometric cytology. J Cell Biol. 1966 Jul;30(1):23–38. doi: 10.1083/jcb.30.1.23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Winterfeld G., Hauff P., Görlich M., Arnold W., Fichtner I., Staab H. J. Investigations of droloxifene and other hormone manipulations on N-nitrosomethylurea-induced rat mammary tumours. 1. Influence on tumour growth. J Cancer Res Clin Oncol. 1992;119(2):91–96. doi: 10.1007/BF01209662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wärri A. M., Huovinen R. L., Laine A. M., Martikainen P. M., Härkönen P. L. Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst. 1993 Sep 1;85(17):1412–1418. doi: 10.1093/jnci/85.17.1412. [DOI] [PubMed] [Google Scholar]
  31. di Salle E., Zaccheo T., Ornati G. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem. 1990 Jun 22;36(3):203–206. doi: 10.1016/0022-4731(90)90005-d. [DOI] [PubMed] [Google Scholar]

Articles from International Journal of Experimental Pathology are provided here courtesy of Wiley

RESOURCES